FULC - CIK 0001680581
Fulcrum Therapeutics, Inc. trades as FULC. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$74.88M. This page tracks Fulcrum Therapeutics, Inc. through 477 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -802.7% to -12.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-01 |
| New insider ownership | 3 | 2026-05-01 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-27 |
The largest companies sharing Fulcrum Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Fulcrum Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Fulcrum Therapeutics, Inc. reported a net loss of $74.88M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.